A systematic review and meta-analysis identified factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents (ESAs).

The VERIFY study results highlight rusfertide's potential as a first-in-class treatment for erythrocytosis in polycythemia vera patients. Among phlebotomy-dependent patients with polycythemia vera, ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...